Ankylosing spondylitis (AS) is a chronic inflammatory form of arthritis that mainly affects the sacroiliac joints, where the spine meets the pelvis, and then the spine itself. Its typical sign is back pain that started before age 45, lasts more than three months, is worse at night and in the morning, and gets better with movement rather than rest. Over years, some spinal bones can fuse, which limits movement.
Doctors now see AS as one end of a wider disease called axial spondyloarthritis (axSpA). In "radiographic" axSpA, the classic AS, damage shows on an X-ray. In "non-radiographic" axSpA, the X-ray is still normal, but an MRI can show inflammation. Diagnosis combines symptoms, an HLA-B27 blood test, CRP and ESR, and imaging; no single test proves it. Treatment starts with exercise and NSAIDs, then biologic injections or JAK inhibitor pills such as upadacitinib (RINVOQ).
Key takeaways
- Axial spondyloarthritis affects about 1.0% to 1.4% of US adults, and classic ankylosing spondylitis about 0.5%, according to national survey data.
- Most people with AS carry HLA-B27, but so do about 6% of Americans: a positive test is a clue, not a diagnosis.
- CRP and ESR are often raised, but normal results do not rule AS out. MRI of the sacroiliac joints can show inflammation before X-ray damage appears.
- The average delay between first symptoms and diagnosis is 6.7 years worldwide, and it tends to be longer in women.
- Exercise plus NSAIDs come first; TNF inhibitors, IL-17 inhibitors and JAK inhibitors follow when inflammation stays active.
What is ankylosing spondylitis?
MedlinePlus describes AS as a chronic form of arthritis that mostly affects the bones and joints at the base of the spine. The joints become swollen and inflamed, and over time the spinal bones may join together. This bony fusion is called ankylosis.
AS belongs to the spondyloarthritis family, with psoriatic arthritis, arthritis of inflammatory bowel disease and reactive arthritis. Compare the main types in our guide to arthritis types, symptoms and tests. The Spondylitis Association of America (SAA) estimates that over 3.2 million US adults live with some form of spondyloarthritis.
Axial spondyloarthritis: AS and non-radiographic axSpA
The SAA explains that radiographic axSpA, commonly called ankylosing spondylitis, shows bone changes or fusion on an X-ray. Non-radiographic axSpA (nr-axSpA) has the same symptoms with a normal X-ray, while MRI can show inflammation. Some people with nr-axSpA later develop X-ray changes; many never do.
Causes and risk factors
The exact cause is unknown. Genes and the environment both play a role. The strongest known genetic factor is HLA-B27. MedlinePlus Genetics notes that other genes, such as ERAP1 and IL23R, are also involved, and that about 75% of children who inherit HLA-B27 from a parent with AS do not develop the disease. The SAA estimates that HLA-B27 accounts for about 30% of the overall genetic risk.
Other risk factors include:
- age: symptoms usually begin between 20 and 40, and almost always before 45;
- sex: AS is more common and often more severe in men, although women are frequently missed;
- family history of AS or spondyloarthritis;
- related conditions: psoriasis, Crohn's disease or ulcerative colitis;
- smoking, which a EULAR review linked with faster X-ray progression.
Ankylosing spondylitis symptoms
The hallmark is inflammatory back pain. The SAA describes it as a dull ache deep in the lower back or buttocks that develops gradually, lasts longer than three months, improves with activity but not with rest, and causes morning stiffness of 30 minutes or more. MedlinePlus notes that it may wake you from sleep.
Other common symptoms include:
- pain where tendons attach to bone, especially the heel (enthesitis);
- swollen hips, knees, ankles or shoulders;
- chest pain or difficulty taking a deep breath when the rib joints are involved;
- fatigue, loss of appetite and weight loss;
- over time, a hunched forward posture.
Beyond the joints: eyes, gut and skin
A large meta-analysis of 156 studies found that about 25.8% of people with AS have had uveitis, 9.3% psoriasis and 6.8% inflammatory bowel disease. Acute iritis, a form of uveitis, typically affects one eye at a time and causes eye pain, redness and sensitivity to light; learn to tell it apart from pink eye in conjunctivitis vs uveitis. Rarer complications include abnormal heart rhythm and scarring of the aortic valve or lungs (MedlinePlus). Skin plaques are covered in our article on psoriasis symptoms and triggers.
Ankylosing spondylitis in women
A 2024 meta-analysis found a diagnostic delay about 1.5 years longer in women, especially in older studies and outside Europe. The SAA notes that women may present atypically, for example with neck pain first. In the BE MOBILE trials of bimekizumab, men made up 72.3% of patients with radiographic disease but only about half of those with nr-axSpA; women responded more slowly in the first months, then showed long-term improvements by one year.
How ankylosing spondylitis is diagnosed
A rheumatologist makes the diagnosis by combining your story, a physical exam, blood tests and imaging. The doctor checks for tenderness over the sacroiliac joints, spine, chest and heels, and measures spinal mobility. Younger age at onset and no eye, gut or skin features are linked with a longer delay.
Doctors often use the 2009 ASAS criteria, for back pain of at least three months that began before 45. A person meets them with sacroiliitis on X-ray or MRI plus at least one spondyloarthritis feature (the "imaging arm"), or with a positive HLA-B27 plus at least two features (the "clinical arm"). In the original validation, the criteria were 82.9% sensitive and 84.4% specific.
MRI and sacroiliitis explained
Sacroiliitis means inflammation of the sacroiliac joints. X-rays show damage (erosions, sclerosis, fusion), which takes years to appear. MRI shows earlier changes, such as bone marrow edema, a sign of active inflammation.
MRI is powerful but must be read in context. In a Swiss study, 63.3% of healthy women who had recently given birth had bone marrow edema near the sacroiliac joints, which can mimic axSpA. Erosions were far less common after childbirth (10% versus 56.7% in axSpA). This is why a "positive MRI" in a young mother needs expert interpretation.
Blood tests for ankylosing spondylitis
MedlinePlus lists the usual tests: HLA-B27, CRP, ESR, a complete blood count, and rheumatoid factor and anti-CCP antibodies, which should be negative. None confirms AS alone.
HLA-B27 positive: what it means
HLA-B27 is an inherited protein on white blood cells. A positive result means you carry it, not that you are sick. In the United States, about 6.1% of the population is HLA-B27 positive. The SAA estimates that no more than 2% of carriers develop spondylitis. In people with AS, HLA-B27 is found in more than 95% of white patients, close to 80% of patients from Mediterranean countries and only about 50% of African American patients. A negative test therefore does not rule out AS. Because it is a gene, the result never changes and does not need repeating.
CRP and ESR: can blood tests be normal?
C-reactive protein (CRP) is made by the liver during inflammation. In axSpA, a raised CRP supports the diagnosis and is built into the ASDAS-CRP disease activity score. The sedimentation rate (ESR) is an older marker. Yes, blood tests can be normal: the SAA notes that raised inflammation markers are not present in all patients and estimates that fewer than 70% of people with AS have a high ESR. This is why the ASAS-EULAR recommendations accept either a high CRP, MRI inflammation or X-ray sacroiliitis as objective proof of inflammation.
Anemia and other routine tests
Chronic inflammation can cause mild to moderate anemia, which adds to fatigue, the SAA explains. A complete blood count detects it. Our guide to anemia symptoms, causes and tests explains how to tell inflammation from iron deficiency. Before bimekizumab, its label asks for tuberculosis screening and liver function tests.
Reference values for ankylosing spondylitis lab tests
Ranges vary between laboratories; compare with the range on your own report.
| Test | Usual adult result (US unit / SI unit) | What it can mean in axial spondyloarthritis |
|---|---|---|
| HLA-B27 | Negative (absent) | Positive in most patients with AS, but also in about 6% of healthy Americans |
| CRP | Below 0.3 mg/dL / below 3 mg/L in most healthy adults | 1-10 mg/dL (10-100 mg/L) is a moderate rise: active inflammation, or another cause such as infection |
| ESR (Westergren) | Men under 50: below 15 mm/h; women under 50: below 20 mm/h (same unit in SI) | Raised in many, but not all, people with AS; also raised by anemia and pregnancy |
| Hemoglobin | Men 13.8-17.2 g/dL / 138-172 g/L; women 12.1-15.1 g/dL / 121-151 g/L | Mildly low: anemia of chronic inflammation, or other causes such as iron deficiency |
| Rheumatoid factor and anti-CCP | Negative | Usually negative in AS; positive results point toward rheumatoid arthritis |
| Creatinine | Men 0.7-1.3 mg/dL / 62-115 µmol/L; women 0.5-0.95 mg/dL / 44-84 µmol/L | Kidney check, useful before and during long-term NSAID use |
How to read your results
Look at the pattern rather than a single number. HLA-B27 positive with a raised CRP and inflammatory back pain makes axSpA likely and justifies an MRI. HLA-B27 positive with normal CRP and mechanical back pain (worse with activity, better with rest) is often a coincidence: in US survey data, chronic back pain affects 19.4% of adults, while axSpA affects only about 1%, so disc problems and osteoarthritis are more likely causes. A negative HLA-B27 does not exclude AS if the symptoms and MRI fit.
For people already diagnosed, CRP is mainly a monitoring tool. A falling CRP after starting a biologic is a good sign, while a normal CRP with severe pain may point to another source of pain, such as a fracture, a disc problem or another condition. If your rheumatoid factor or anti-CCP is positive, your doctor will reconsider rheumatoid arthritis; the autoimmune panel explains these antibodies.
Ankylosing spondylitis treatment
The goal is to control pain and stiffness, protect function and prevent damage. The 2022 ASAS-EULAR recommendations and the 2019 US ACR/SAA/SPARTAN guideline follow a similar sequence.
First line: exercise and NSAIDs
Non-drug care comes first: regular exercise and physical therapy, and, as the NIAMS advises, stopping smoking. NSAIDs, such as ibuprofen or naproxen, are the first-choice drugs; MedlinePlus advises talking to your provider before daily long-term use. Long-term glucocorticoids are discouraged, and conventional drugs such as sulfasalazine or methotrexate are discouraged for purely spinal disease. The 2019 US guideline keeps sulfasalazine for persistent swollen peripheral joints when TNF inhibitors cannot be used.
Biologics and JAK inhibitors
If disease activity stays high (ASDAS of 2.1 or more) despite at least two NSAIDs, and there is objective inflammation (high CRP, MRI inflammation or X-ray sacroiliitis), the 2022 recommendations advise a biologic or a targeted pill. Current practice is to start with a TNF inhibitor (adalimumab, etanercept, infliximab, certolizumab, golimumab) or an IL-17 inhibitor (secukinumab, ixekizumab, bimekizumab). The 2019 US guideline favored a TNF inhibitor as the first biologic. JAK inhibitors are tablets: upadacitinib (RINVOQ) is FDA-approved for AS and nr-axSpA after an inadequate response to a TNF blocker, and tofacitinib is another option. Its label carries a boxed warning on serious infections, cancer, heart events and blood clots, and requires tuberculosis screening; see our tuberculosis test guide.
The other conditions you have help choose the drug. TNF monoclonal antibodies are preferred for recurrent uveitis or inflammatory bowel disease (such as colitis), and IL-17 inhibitors for significant psoriasis. If the first drug fails, the guideline asks doctors to recheck the diagnosis and look for other causes of pain before switching. In sustained remission, tapering a biologic can be considered.
Injections and surgery
"Ankylosing spondylitis injection" usually refers to biologics given under the skin, such as bimekizumab 160 mg every four weeks. Short courses of corticosteroids may be used for flares, MedlinePlus notes. Surgery, such as hip replacement, may be done if pain or joint damage is severe, and the 2022 recommendations also cover surgery for spinal fractures and deformity.
Living with AS: exercise, sleep and natural remedies
Exercise is treatment. A 2023 meta-analysis found that exercise programs moderately improve disease activity, function and spinal mobility, whatever the type; combining flexibility and strengthening gave the largest gains in mobility.
Sleep problems are very common: a meta-analysis of 18 studies found them in 53% of people with AS. Night pain and stiffness from inflammation are major drivers, so controlling inflammation comes first. MedlinePlus suggests lying flat on your back at night to keep a normal posture. Loud snoring with daytime sleepiness deserves a separate check for sleep apnea.
Natural approaches with real support are regular exercise, not smoking, a healthy diet and stress management, all recommended by the NIAMS. No supplement or diet has been shown to stop AS.
Complications and long-term outlook
MedlinePlus notes that most people with AS function well unless they have extensive damage to the hips or spine. Fused spinal bones are prone to fracture (MedlinePlus Genetics). A 2025 review of 1,972 patients with AS and neck fractures found them mostly at the C5-C7 level, with an overall mortality of 2.9%, so any new neck pain after a fall needs urgent imaging. Ask whether you need a bone density test; read more about osteoporosis. If you take NSAIDs every day, ask how often your kidney function (creatinine) should be checked.
When to see a doctor
See your doctor, and ask about a rheumatology referral, if you are under 45 and have back or buttock pain for more than three months that is worse at night or in the morning and better with exercise, especially with uveitis, psoriasis, bowel disease or a family history of AS. If you have AS, report new symptoms, a red painful eye or signs of infection on treatment.
Call 911 or go to the emergency room if you have:
- a fall or minor injury followed by new neck or back pain, especially with a fused spine;
- numbness, weakness or tingling in the arms or legs, or loss of bladder or bowel control;
- chest pain, fainting or a very irregular heartbeat;
- sudden vision loss or a very painful red eye with light sensitivity;
- high fever or breathing difficulty on a biologic or JAK inhibitor.
Latest scientific advances in ankylosing spondylitis
Bimekizumab: dual IL-17 blockade with three-year results
Bimekizumab blocks both IL-17A and IL-17F. In the phase 3 BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743) trials, improvements in symptoms, hs-CRP and MRI inflammation seen at 16 weeks were sustained at 52 weeks. The three-year extension, published in 2026, found that 57.0% of patients had low disease activity at week 164, with uveitis and inflammatory bowel disease remaining rare (1.5 and 0.5 cases per 100 patient-years). Oral thrush (candidiasis) was the most frequent fungal infection.
Upadacitinib for non-radiographic axSpA
In the SELECT-AXIS 2 trial (NCT04169373, Lancet 2022), 45% of people with nr-axSpA on upadacitinib 15 mg reached a 40% improvement (ASAS40) at 14 weeks, versus 23% on placebo. A 2024 network meta-analysis of 44 trials found that TNF antibodies, IL-17 inhibitors and JAK inhibitors all appear to protect against anterior uveitis compared with placebo, with no significant difference between classes.
Secukinumab vs adalimumab: X-ray progression
The SURPASS head-to-head trial (859 patients, 2024) compared secukinumab with an adalimumab biosimilar over two years. About two-thirds of patients in each group had no X-ray progression of the spine, with no significant difference. For you: other factors (eyes, gut, skin, preference) can guide the choice.
Seniprutug: targeting the T cells behind the disease
A 2026 review describes T cells carrying a TRBV9 receptor that expand in the joints and eyes of HLA-B27 positive patients. Seniprutug (BCD-180), an antibody that removes these cells, was given as three infusions (weeks 0, 12 and 36) in the phase 2 ELEFTA trial (260 patients): 51.4% reached ASAS40 at week 24 on the higher dose, versus 24% on placebo. A phase 3 trial (NCT06333210, 421 patients) is under way. It is not approved in the US.
A US guideline update in preparation
SPARTAN members surveyed in 2024 favored treating axSpA as a single disease in the next US guideline, with drug recommendations as the top priority. As of November 2026, we found no published 2025 update in PubMed; the 2019 version and the 2022 ASAS-EULAR recommendations remain the references.
Which tests can help?
If AS or axSpA is suspected or confirmed, ask your doctor whether these tests are right for you:
- HLA-B27, once, as part of the first workup;
- CRP and ESR, at diagnosis and then to follow disease activity;
- a complete blood count if you are tired or pale;
- rheumatoid factor and anti-CCP to rule out rheumatoid arthritis;
- creatinine and liver tests on long-term treatment, and tuberculosis screening before a biologic or JAK inhibitor;
- a lipid panel and a bone density scan;
- X-ray or MRI of the sacroiliac joints.
Glossary
- Axial spondyloarthritis (axSpA): inflammatory arthritis of the spine and sacroiliac joints, with or without X-ray damage.
- Sacroiliitis: inflammation of the sacroiliac joints, where the spine meets the pelvis.
- Enthesitis: inflammation where a tendon or ligament attaches to bone, such as the heel.
- HLA-B27: an inherited protein on white blood cells strongly linked to AS.
- ASDAS: a disease activity score combining symptoms and CRP; below 2.1 means low activity.
Frequently asked questions
Why is my ankylosing spondylitis getting worse?
Common reasons are uncontrolled inflammation, missed medication, smoking and inactivity. Sometimes the pain has another cause, such as a disc problem, a fracture or hip damage; the 2022 recommendations ask doctors to look for these before changing treatment. CRP and sometimes MRI show whether inflammation is active.
Is HLA-B27 positive the same as having AS?
No. About 6% of Americans carry HLA-B27, and most never develop AS. It only matters with typical symptoms or imaging changes, and a negative result does not rule AS out.
Can blood tests be normal with ankylosing spondylitis?
Yes. CRP and ESR are normal in a share of people with AS, especially with non-radiographic axSpA. MRI of the sacroiliac joints can show inflammation that blood tests miss.
Can gabapentin help ankylosing spondylitis?
Gabapentin is a nerve-pain medicine, not an anti-inflammatory treatment, and we found no randomized trials of it in AS. It does not replace NSAIDs or biologics; discuss any pain medicine with your doctor.
What are some natural remedies for spondylitis?
Daily exercise is the best-proven natural remedy, especially combined stretching and strengthening. Quitting smoking, a healthy diet and stress management are also recommended by the NIAMS. No supplement has been proven to slow AS.
How can I get better sleep with ankylosing spondylitis?
Treat the inflammation first, because night pain and stiffness are common causes of poor sleep. Stay active during the day, lie flat on your back, and tell your doctor if you still wake from pain or snore loudly.
Is ankylosing spondylitis a disability, and does it shorten life?
AS is a chronic condition, but most people keep working and stay active with modern treatment. Whether it qualifies for disability benefits depends on how much it limits your function. A 35-year Swiss study found a modestly higher death rate in radiographic AS than in the general population (standardized mortality ratio 1.37), but not in non-radiographic axSpA.
Does ankylosing spondylitis affect women differently?
Women are diagnosed later, on average, and may present atypically, for example with neck pain first. Men are more often affected by radiographic AS. Women respond well to treatment, sometimes more slowly at first.
Sources
- Ramiro S et al. — ASAS-EULAR recommendations for axSpA: 2022 update — Ann Rheum Dis, 2023 — doi.org
- Ward MM et al. — 2019 ACR/SAA/SPARTAN recommendations for AS and nr-axSpA — Arthritis Rheumatol, 2019 — doi.org
- Choufani M, Ermann J — Updating the 2019 ACR/SAA/SPARTAN recommendations — Curr Rheumatol Rep, 2024 — doi.org
- Rudwaleit M et al. — ASAS classification criteria for axSpA (part II) — Ann Rheum Dis, 2009 — doi.org
- Zhao SS et al. — Diagnostic delay in axial spondyloarthritis: meta-analysis — Rheumatology, 2021 — doi.org
- Bandinelli F et al. — Sex bias in diagnostic delay of axSpA: meta-analysis — J Pers Med, 2024 — doi.org
- Stolwijk C et al. — Extra-articular manifestations in AS — Ann Rheum Dis, 2015 — doi.org
- Reveille JD, Weisman MH — Back pain, axSpA and HLA-B27 in the United States — Am J Med Sci, 2013 — doi.org
- Li Z et al. — HLA-B27, axial spondyloarthritis and survival — Ann Rheum Dis, 2023 — doi.org
- Baraliakos X et al. — Bimekizumab: 52-week BE MOBILE results — Ann Rheum Dis, 2024 — doi.org
- Baraliakos X et al. — Bimekizumab over 3 years — J Rheumatol, 2026 — doi.org
- Rudwaleit M et al. — Bimekizumab in men and women with axSpA — Rheumatology, 2026 — doi.org
- Deodhar A et al. — Upadacitinib in nr-axSpA (SELECT-AXIS 2) — Lancet, 2022 — doi.org
- Baraliakos X et al. — Secukinumab vs adalimumab biosimilar (SURPASS) — Arthritis Rheumatol, 2024 — doi.org
- Bechman K et al. — Uveitis with biologics or targeted synthetics in axSpA — Arthritis Rheumatol, 2024 — doi.org
- Nasonov EL et al. — Seniprutug (BCD-180) in radiographic axSpA: ELEFTA phase 2 — Dokl Biochem Biophys, 2025 — doi.org
- Um J, Paley MA — Axial spondyloarthritis: a T cell story — Curr Rheumatol Rep, 2026 — doi.org
- Salari N et al. — Sleep disturbance in AS: meta-analysis — Adv Rheumatol, 2023 — doi.org
- Boudjani R et al. — Exercise programs in AS: meta-analysis — Disabil Rehabil, 2023 — doi.org
- Agten CA et al. — Postpartum bone marrow edema may mimic sacroiliitis — AJR, 2018 — doi.org
- Wieczorek M et al. — Smoking, alcohol and outcomes in RMDs (EULAR) — RMD Open, 2022 — doi.org
- Musa G et al. — Cervical fractures in AS: systematic review — Neurosurg Rev, 2025 — doi.org
- ClinicalTrials.gov — BCD-180 (seniprutug) in active axial spondyloarthritis, NCT06333210 — clinicaltrials.gov
- MedlinePlus — Ankylosing spondylitis — medlineplus.gov
- MedlinePlus — HLA-B27 antigen — medlineplus.gov
- MedlinePlus Genetics — Ankylosing spondylitis — medlineplus.gov
- MedlinePlus — Ankylosing Spondylitis health topic (NIAMS) — medlineplus.gov
- MedlinePlus — C-reactive protein; ESR; Hemoglobin; Creatinine blood test — medlineplus.gov, ESR, hemoglobin, creatinine
- Spondylitis Association of America — Overview of Spondyloarthritis — spondylitis.org
- Spondylitis Association of America — Ankylosing Spondylitis: Diagnosis — spondylitis.org
- DailyMed — BIMZELX (bimekizumab) prescribing information, 2026 — dailymed.nlm.nih.gov
- DailyMed — RINVOQ (upadacitinib) prescribing information, 2026 — dailymed.nlm.nih.gov
Further reading
- High CRP levels: what your result really means
- Autoimmune disease symptoms and lab tests
- Fecal calprotectin test: what results mean
- Hemoglobin levels: what your blood test means
- Vitamin D deficiency: symptoms, causes and treatment
- Sleep apnea: symptoms, tests and treatment
Understand your lab results with AI DiagMe
Ankylosing spondylitis shows up in several blood tests: HLA-B27, CRP, ESR, hemoglobin, and kidney and liver tests. AI DiagMe reads your lab report in minutes, explains each value in plain language, highlights patterns such as a high CRP with mild anemia, and suggests questions to ask your rheumatologist. Upload your lab results to AI DiagMe for a clear, personal report.



